R&D

2854-LB: Efficacy and Safety of CU01-1001 in Patients with Diabetic Kidney Disease: Significant Reduction in Urine Albumin–to–Creatinine Ratio (uACR)

The REDD1–NF-κB–miRNAs–eNOS/SIRT1 axis mediates obesity-induced endothelial cell senescence and hypertension

CU104, a novel barrier function enhancer, improves colitis via modulation of barrier function and immune cell recruitment

CU06-1004 inhibits the progression of chronic colitis and colitis-associated colorectal cancer by suppressing inflammation

Phase 2a Study of CU06-1004, an Oral Endothelial Dysfunction Blocker for the Treatment of Diabetic Macular Edema

CU06-1004 alleviates oxidative stress and inflammation on folic acid-induced acute kidney injury in mice

A novel small molecule, CU05-1189, targeting the pleckstrin homology domain of PDK1 suppresses VEGF-mediated angiogenesis and tumor growth by blocking the Akt signaling pathway

CU06-1004 as a promising strategy to improve anti-cancer drug efficacy by preventing vascular leaky syndrome

CU06-1004 alleviates vascular hyperpermeability in a murine model of hereditary angioedema by protecting the endothelium

Efficacy of CU06-1004 via regulation of inflammation and endothelial permeability in LPS-induced acute lung injury

Long-term administration of CU06-1004 ameliorates cerebrovascular aging and BBB injury in aging mouse model

Oral administration of CU06-1004 attenuates vascular permeability and stabilizes neovascularization in retinal vascular diseases

821-P: Randomized Clinical Trial on the Renoprotective Effect of CU01-10in Patients with Diabetic Kidney Disease (DKD)

CU06-1004 modulates the adenosine monophosphate (AMP)-associated protein kinase (AMPK) signaling pathway and inhibits lipogenesis in 3T3-L1 adipocytes and high-fat diet-induced obese mice

CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia-reperfusion injury

CU06-1004-Induced Vascular Normalization Improves Immunotherapy by Modulating Tumor Microenvironment via Cytotoxic T Cells

The endothelial dysfunction blocker CU06-1004 ameliorates choline-deficient L-amino acid diet-induced non-alcoholic steatohepatitis in mice

CU06-1004 Alleviates Experimental Colitis by Modulating Colonic Vessel Dysfunction

CU06-1004 (endothelial dysfunction blocker) ameliorates astrocyte end-feet swelling by stabilizing endothelial cell junctions in cerebral ischemia/reperfusion injury

Sac-1004, a vascular leakage blocker, reduces cerebral ischemia-reperfusion injury by suppressing blood-brain barrier disruption and inflammation

Sac-1004, a Pseudo-Sugar Derivative of Cholesterol, Restores Erectile Function through Reconstruction of Nonleaky and Functional Cavernous Angiogenesis in the Streptozotocin Induced Diabetic Mouse